Factors predicting better prognosis in patients with brain cancer, such as IDH mutations and 1p/19q codeletion, were often lost in the grade II/III primary cells, whereas those that predicted poor outcome, such as chromosome 7p gain and10q loss, were preserved in the GBM primary cells. This evidence concerns the gene IDH2 and glioblastoma.